Clinical trials: Liver Inflammation
Rift Valley Fever
Safety and Immunogenicity Study of Rift Valley Fever Vaccine
This study is designed to determine the safety and immunogenicity of a Rift Valley Fever (RVF) Vaccine
- Trial name
- RVF (NCT00584194)
- Testing
- TSI-GSD 200 RVF Vaccine
- Where
- United States
- Volunteers
- 278 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Liver Transplant, Hepatitis C
The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients
This is an open-label, pilot trial to test the safety and efficacy of transplantation of livers from Hepatitis C seropositive non-viremic (HCV Ab+/NAT-) and HCV seropositive viremic (HCV Ab+/NAT+) donors to HCV seronegative…
- Trial name
- NCT03819322
- Testing
- sofosbuvir/velpatasvir
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Fernanda P Silveira, MD, MS
Hepatitis C, Chronic
Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685)
This is a controlled, randomized, parallel-groups, open-label, multinational study designed to evaluate the efficacy and safety of PEG-Intron® (pegylated interferon alfa-2b) plus Rebetol® (ribavirin) in subjects with chronic…
- Trial name
- NCT00265395
- Testing
- Combination of pegylated interferon alfa-2b (PEG-Intron®) and ribavirin (Rebetol®), Combination of pegylated interferon alfa-2b and ribavirin
- Volunteers
- 1,428 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis B Chronic Infection, Pregnancy
Maternal Antiviral Prophylaxis to Prevent Perinatal Transmission of Hepatitis B Virus in Thailand
Chronic hepatitis B (CHB) infection is complicated by cirrhosis and liver cancer. In Thailand, 7% of adults are chronically infected by Hepatitis B virus (HBV).
- Trial name
- iTAP (NCT01745822)
- Testing
- tenofovir disoproxil fumarate
- Where
- 17 sites in Thailand
- Volunteers
- 654 people
- Sponsor
- Institut de Recherche pour le Developpement
Hepatitis C
Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment
The study is to investigate whether participants with hepatitis C virus (HCV) genotype 1 who have a history of non-response/relapse to peginterferon alfa-2a (PEG) and ribavirin (RBV) may benefit from treatment with triple therapy…
- Trial name
- NCT01183169
- Testing
- Alisporivir, Peginterferon alfa-2a, Ribavirin
- Where
- 75 sites in United States, Australia and 12 more
- Volunteers
- 459 people
- Sponsor
- Debiopharm International SA
Tetanus, Poliomyelitis
Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.
This study will evaluate the safety and immunogenicity of GSK Biologicals' GSK2202083A vaccine given as a three-dose vaccination course at 3, 5 and 11 months of age.
- Conditions
- Tetanus, Poliomyelitis, Neisseria Meningitidis, Haemophilus Influenzae Type b
- Trial name
- NCT00871741
- Testing
- GSK2202083A vaccine, Infanrix hexa, Menjugate
- Where
- 8 sites in Slovakia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
Effect of Exenatide on Liver and Heart Fat and Inflammation
The purpose of this study is to examine the effect of exenatide on liver and heart (myocardial) fat and inflammation.
- Trial name
- NCT01951651
- Testing
- Exenatide, Glipizide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Baylor College of Medicine
Hepatitis C
LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients
The predominant remaining questions for post-transplant treatment of Hepatitis C virus (HCV) in the DAA (direct acting anti-virals) era are whether a ribavirin-free regimen is possible and whether pre-emptive treatment is now a…
- Trial name
- NCT02631772
- Testing
- Sofosbuvir/Ledipasvir x 12 weeks, Sofosbuvir/Ledipasvir + Ribavirin x 12 weeks
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- Medical University of South Carolina
Hepatitis B
Modified Process Hepatitis B Vaccine in Japanese Young Adults (V232-062)
This is a study to evaluate immunogenicity, safety, and tolerability of 2XP HEPTAVAX™-II compared with the 1XP HEPTAVAX™-II in healthy Japanese young adults.
- Trial name
- NCT01463683
- Testing
- 2XP HEPTAVAX™-II SC, 1XP HEPTAVAX™-II SC, 2XP HEPTAVAX™-II IM
- Volunteers
- 722 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis B, Chronic
A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon Alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B
This study is a long-term post-treatment follow-up to study WV19432, which evaluated the efficacy and safety of PEGASYS in patients with HBeAg positive chronic hepatitis B (CHB).Patients who received treatment with PEGASYS, and…
- Trial name
- NCT00927082
- Testing
- peginterferon alfa-2a [Pegasys]
- Where
- 31 sites in Australia, Brazil and 8 more
- Volunteers
- 383 people
- Sponsor
- Hoffmann-La Roche
Hepatitis B
Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB)
This study is intended to evaluate if 12 or 24 weeks of treatment with GSK3228836 followed by up to 24 weeks of pegylated interferon (PegIFN) can increase the rate of hepatitis B virus surface antigen (HBsAg) loss in participants…
- Trial name
- B-Together (NCT04676724)
- Testing
- GSK3228836, PegIFN, NA therapy
- Where
- 49 sites in United States, Canada and 9 more
- Volunteers
- 108 people
- Sponsor
- GlaxoSmithKline
Hepatitis B
A Study to Qualify an In-house Reference Standard Batch of Sci-B-Vac™
Each Sci-B-Vac™ lot to be released to the market is tested in comparison to a reference batch,which has to be tested in a human clinical trial. This study was conducted by SciVac Ltd.
- Trial name
- NCT04179786
- Testing
- Sci-B-Vac™
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- VBI Vaccines Inc.
Chronic Hepatitis C, Hepatitis C
Post-marketing Surveillance of HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584)
The objective of the study was to assess the safety and efficacy of peginterferon alfa-2b (PEG-IFN alfa-2b) and ribavirin (RBV) administered to participants coinfected with Human Immunodeficiency Virus (HIV) and Hepatitis C Virus…
- Conditions
- Chronic Hepatitis C, Hepatitis C, HIV Infections
- Trial name
- NCT00736242
- Testing
- PEG-IFN alfa-2b, RBV
- Volunteers
- 232 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C Virus Infection
A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection
The purpose of this study is to evaluate the safety and efficacy of Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) with sofosbuvir (SOF) with or without ribavirin (RBV) in adults with Genotype 2 Chronic Hepatitis C Virus (HCV)…
- Trial name
- Quartz II/III (NCT02292719)
- Testing
- OBV/PTV/r, Sofosbuvir, Ribavirin (RBV)
- Volunteers
- 70 people
- Sponsor
- AbbVie
Hepatitis B
An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection
The main purpose of this study is to evaluate efficacy of 24 weeks of study treatment, in terms of changes in hepatitis B surface antigen (HBsAg) levels.
- Trial name
- NCT03361956
- Testing
- JNJ-56136379, NA (ETV or TDF)
- Where
- 76 sites in United States, Belgium and 17 more
- Volunteers
- 232 people
- Sponsor
- Janssen Sciences Ireland UC
Chronic Hepatitis C Infection
Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection
This is a phase 3, double-blinded, multicenter study. The study will consist of 2 substudies: Substudy 1 (SS1) will be double-blinded and enroll non-cirrhotic subjects and Substudy 2 (SS2) will be open label and enroll subjects…
- Trial name
- GIFT I (NCT02023099)
- Testing
- ABT-450/r/ABT-267
- Volunteers
- 363 people
- Sponsor
- AbbVie
Chronic HCV Infection
Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Chronic Genotype 1 or 3 HCV Infection
This study will evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir (SOF) + ribavirin (RBV) in treatment-naive adults with chronic genotype 1 or 3 hepatitis C virus (HCV) infection.
- Trial name
- NCT02074514
- Testing
- Sofosbuvir, RBV
- Where
- 13 sites in India
- Volunteers
- 117 people
- Sponsor
- Gilead Sciences
Hepatitis C Virus Infection
A Multiple-Dose Study to Evaluate MK-1075 in Hepatitis C Virus (HCV) Infected Participants (MK-1075-004)
This study will evaluate safety, pharmacokinetics (PK), and the ability of MK-1075 to suppress viral load (VL) in HCV-infected participants during 7 days of once daily dose administration.
- Trial name
- NCT02461563
- Testing
- 200 mg MK-1075, 400 mg MK-1075, 800 mg MK-1075
- Volunteers
- 12 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV Infection
This study will evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir plus ribavirin administered for 16 weeks and 24 weeks in participants with chronic genotype 1 (GT1) or genotype 3 (GT3) hepatitis C virus…
- Trial name
- NCT01896193
- Testing
- SOF, RBV
- Where
- 16 sites in Russia
- Volunteers
- 127 people
- Sponsor
- Gilead Sciences
Hepatitis B, Chronic
Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection
A First-Time-In-Human study on GSK's therapeutic vaccines to evaluate the reactogenicity, safety, immunogenicity and efficacy on reduction of serum HBV surface antigen in HBV suppressed participants under nucleo(s)tide treatment.
- Trial name
- NCT03866187
- Testing
- ChAd155-hIi-HBV low dose formulation, ChAd155-hIi-HBV high dose formulation, HBc-HBs/AS01B-4 low dose formulation
- Where
- 43 sites in Belgium, France and 7 more
- Volunteers
- 236 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.